Gain Therapeutics, Inc.(GANX)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .

Gain Therapeutics, Inc. (GANX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. GANX is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.2m in revenue and is scored on the micro-cap board instead. Top institutional holders of GANX by reported 13-F value include MARSHALL WACE, LLP, Potomac Capital Management, GSA CAPITAL PARTNERS LLP, based on the most recent SEC filings. GANX trades on the Nasdaq exchange and files with the SEC under CIK 1819411. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GANX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Gain Therapeutics, Inc. directly from SEC EDGAR.

Net Income

$-4.7M

GANX key financials by period

Gain Therapeutics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodFormRevenueNet incomeOperating margin
FY 202310-K$55.2K$-22.3M—
FY 202210-K$140.1K$-17.6M—
FY 202110-K$165.0K$-13.9M—
FY 202010-K$28.9K$-3.6M—

Institutions holding GANX

Institutional investors reporting a position in Gain Therapeutics, Inc. on SEC Form 13F.
InstitutionSharesValueReported
MARSHALL WACE, LLP1,923,546$3.9M2026-06-30
Potomac Capital Management946,400$1.9M2026-06-30
GSA CAPITAL PARTNERS LLP632,131$1.3M2026-06-30
Cambridge Investment Research Advisors568,645$1.2M2026-06-30
DME Capital Management566,130$1.1M2026-06-30
JONES FINANCIAL COMPANIES LLLP608,592$1.1M2026-06-30
VANGUARD CAPITAL MANAGEMENT480,269$974.9K2026-06-30
GEODE CAPITAL MANAGEMENT453,501$921.4K2026-06-30
BlackRock274,957$558.2K2026-06-30
VANGUARD FIDUCIARY231,534$470.0K2026-06-30
SEC EDGAR: CIK 1819411 →
GANX

Gain Therapeutics, Inc.

GANX
NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.2M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Price Chart

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.
Reading the latest SEC filing… (first load can take ~20s)

Key Metrics

Net Income

Q2 2026
EDGAR

$-4.68M

EPS (Diluted)

Q2 2026
EDGAR

$-0.11

Debt/Equity

Q2 2026
EDGAR

0.04

Top Institutional Holders

as of Q2 2026
$17.72M total
MARSHALL WACE, LLP
$3.90M+8.7%
Potomac Capital Management, Inc.
$1.92M-6.2%
GSA CAPITAL PARTNERS LLP
$1.28M+102.3%
Cambridge Investment Research Advisors, Inc.
$1.15M0.0%
DME Capital Management, LP
$1.15M0.0%
JONES FINANCIAL COMPANIES LLLP
$1.07M-3.6%
VANGUARD CAPITAL MANAGEMENT LLC
$974.9K+20.1%
GEODE CAPITAL MANAGEMENT, LLC
$921.4K+1.4%
BlackRock, Inc.
$558.2K+22.2%
VANGUARD FIDUCIARY TRUST CO
$470.0K+0.7%

Financial Trends

Revenue & Net Income

Earnings Per Share

Loading ratio trend…